Comparative Pharmacology
Head-to-head clinical analysis: ARICEPT versus RAZADYNE ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARICEPT versus RAZADYNE ER.
ARICEPT vs RAZADYNE ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversible inhibitor of acetylcholinesterase, increasing acetylcholine levels in the synaptic cleft of the central nervous system.
Reversible, competitive acetylcholinesterase inhibitor, increasing acetylcholine concentrations in the synaptic cleft of the central nervous system, particularly enhancing cholinergic neurotransmission in the cerebral cortex and hippocampus.
Initial: 5 mg orally once daily for 4-6 weeks; may increase to 10 mg once daily. Maximum: 10 mg per day. Route: oral. Frequency: once daily.
16 mg orally once daily in the morning; may increase to 24 mg once daily after minimum of 4 weeks; maximum dose 24 mg/day.
None Documented
None Documented
70 hours (terminal elimination half-life; steady-state reached in 15-21 days; once-daily dosing appropriate)
Terminal half-life approximately 7-8 hours; clinical context: supports twice-daily dosing
Renal (57% unchanged drug, 17% as metabolites), fecal (30%), biliary (minimal)
Renal: 95% as unchanged drug and metabolites; Fecal: 5%
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor